Evidence map›Paper›PMID 42294482›Full record

ArticleImmuno-oncology technology2026

Th17-mediated antitumor immunity in patient-derived organoid and autologous immune cell cocultures predicts response to immunotherapy in head and neck cancer.

P Meißner, P Kaps, T Momper, A Wolff, I Raabe, D F Strueder, U Langenkamp, J Brandstetter, C Junghanss, A S Becker and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Immuno-oncology technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

P MeißnerDepartment of Internal Medicine-Clinic and Polyclinic for Hematology, Hemostaseology, Oncology, Stem Cell Therapy and Palliative Medicine, Rostock University Medical Center, Rostock, Germany.
P KapsDepartment of Internal Medicine-Clinic and Polyclinic for Hematology, Hemostaseology, Oncology, Stem Cell Therapy and Palliative Medicine, Rostock University Medical Center, Rostock, Germany.
T MomperDepartment of Otorhinolaryngology, Head and Neck Surgery "Otto Koerner," Rostock University Medical Center, Rostock, Germany.
A WolffDepartment of Internal Medicine-Clinic and Polyclinic for Hematology, Hemostaseology, Oncology, Stem Cell Therapy and Palliative Medicine, Rostock University Medical Center, Rostock, Germany.
I RaabeDepartment of Internal Medicine-Clinic and Polyclinic for Hematology, Hemostaseology, Oncology, Stem Cell Therapy and Palliative Medicine, Rostock University Medical Center, Rostock, Germany.
D F StruederDepartment of Otorhinolaryngology, Head and Neck Surgery "Otto Koerner," Rostock University Medical Center, Rostock, Germany.
U LangenkampDepartment of Internal Medicine-Clinic and Polyclinic for Hematology, Hemostaseology, Oncology, Stem Cell Therapy and Palliative Medicine, Rostock University Medical Center, Rostock, Germany.
J BrandstetterDepartment of Internal Medicine-Clinic and Polyclinic for Hematology, Hemostaseology, Oncology, Stem Cell Therapy and Palliative Medicine, Rostock University Medical Center, Rostock, Germany.
C JunghanssDepartment of Internal Medicine-Clinic and Polyclinic for Hematology, Hemostaseology, Oncology, Stem Cell Therapy and Palliative Medicine, Rostock University Medical Center, Rostock, Germany.
A S BeckerInstitute of Pathology, Rostock University Medical Center, Rostock, Germany.
A ZimpferInstitute of Pathology, Rostock University Medical Center, Rostock, Germany.
C MaletzkiDepartment of Internal Medicine-Clinic and Polyclinic for Hematology, Hemostaseology, Oncology, Stem Cell Therapy and Palliative Medicine, Rostock University Medical Center, Rostock, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Immune checkpoint inhibitor (ICI) therapy improves survival in head and neck squamous cell carcinoma (HNSCC), yet only some patients benefit, highlighting the need for early identification of responders and functional evaluation of tumor-immune interactions. We developed an autologous coculture platform combining patient-derived organoids (PDOs) with peripheral blood mononuclear cells (PBMCs) to assess immune responses and correlate preclinical findings with clinical outcomes. Material and methods: PDOs from HNSCC specimens were expanded and cocultured with PBMCs, followed by treatment with ICIs targeting programmed cell death protein 1 (PD-1), lymphocyte-activation gene 3 (LAG-3), or their combination. Results: PBMCs were enriched for CD4 Conclusion: Collectively, this autologous PDO-PBMC coculture platform, combined with longitudinal cytokine profiling, captures patient-specific tumor-immune interactions and interpatient heterogeneity, providing a framework for real-time response prediction, biomarker discovery, and personalized immunotherapy in HNSCC.

Indexed as

antigen-specific T cellscytotoxicityT cell exhaustionT cell stimulationtumor architecture

Identifiers

PMID42294482
PMCPMC13264355

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.